



**HAL**  
open science

# Thyroid dysfunction in patients with diabetes: Clinical implications and screening strategies

Raghu Kadiyala, R Peter, O Okosieme

## ► To cite this version:

Raghu Kadiyala, R Peter, O Okosieme. Thyroid dysfunction in patients with diabetes: Clinical implications and screening strategies. *International Journal of Clinical Practice*, 2010, 64 (8), pp.1130. 10.1111/j.1742-1241.2010.02376.x . hal-00552649

**HAL Id: hal-00552649**

**<https://hal.science/hal-00552649v1>**

Submitted on 6 Jan 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Thyroid dysfunction in patients with diabetes:  
Clinical implications and screening strategies**

Journal:	<i>International Journal of Clinical Practice</i>
Manuscript ID:	IJCP-12-09-0761.R1
Manuscript Type:	Non-Systematic Review
Date Submitted by the Author:	02-Feb-2010
Complete List of Authors:	Kadiyala, Raghu; Prince Charles Hospital, Endocrinology and Diabetes Department Peter, R; University Hospital of Wales, Diabetes & Endocrinology Okosieme, O; Prince Charles Hospital, Endocrinology and Diabetes Department
Specialty area:	



1  
2  
3 **Thyroid dysfunction in patients with diabetes:**

4  
5 **Clinical implications and screening strategies**

6  
7  
8  
9  
10 Kadiyala R, Peter R\* and Okosieme OE

11  
12  
13  
14  
15 Prince Charles Hospital, Cwm Taf Local Health Board

16  
17 Merthyr Tydfil, Mid Glamorgan, CF47 9DT, UK

18  
19  
20  
21  
22 \*Neath Port Talbot Hospital

23  
24 Abertawe Bro Morgannwg University Health Board

25  
26 Baglan Way, Port Talbot, SA12 7BX.

27  
28  
29  
30  
31 Correspondence to:

32  
33  
34 Dr Onyebuchi E Okosieme MD MRCP

35  
36 Endocrinology and Diabetes Department

37  
38 Prince Charles Hospital, Cwm Taf Local Health Board

39  
40 Merthyr Tydfil, Mid Glamorgan, CF47 9DT, UK

41  
42  
43 E-mail: okosiemeoe@cf.ac.uk

44  
45  
46 Tel: 01685 728353, Fax: 01685 728448

47  
48  
49  
50  
51 **Running title:** Thyroid dysfunction and diabetes

52  
53 **Key words:** Thyroid dysfunction, diabetes mellitus, cardiovascular disease, screening

54  
55 **Abstract:** 246

56  
57  
58 **Manuscript:** [4009](#)

## Abstract

**Background:** Patients with diabetes mellitus are at increased risk of thyroid disease.

The frequency of thyroid dysfunction in diabetic patients is higher than that of the general population and up to a third of patients with type 1 diabetes (T1DM) ultimately develop thyroid dysfunction. Unrecognised thyroid dysfunction may impair metabolic control and add to cardiovascular disease risk in diabetic patients. **Aims:**

Our aims were to review the current literature on the association between thyroid dysfunction and diabetes mellitus, to highlight relevant clinical implications, and to examine present thyroid disease screening strategies in routine diabetes care. **Results:**

The pleiotropic effects of thyroid hormones on various metabolic processes are now better understood. Uncontrolled hyperthyroidism in diabetic patients may trigger hyperglycaemic emergencies while recurrent hypoglycaemic episodes have been reported in diabetic patients with hypothyroidism. Furthermore, thyroid dysfunction may amplify cardiovascular disease risk in diabetic patients through inter-relationships with dyslipidaemia, insulin resistance and vascular endothelial dysfunction. However, the significance of subclinical degrees of thyroid dysfunction remains to be clarified. While these developments have implications for diabetic patients a consensus is yet to be reached on optimal thyroid screening strategies in diabetes management. **Conclusions:** The increased frequency of thyroid dysfunction in diabetic patients and its likely deleterious effects on cardiovascular and metabolic function calls for a systematic approach to thyroid disease screening in diabetes. Routine annual thyroid testing should be targeted at diabetic patients at risk of thyroid dysfunction such as patients with T1DM, positive thyroid autoantibodies or high-normal TSH concentrations.

**Message for the clinic**

Clinicians should be aware of the frequent co-existence of thyroid dysfunction and diabetes mellitus. Periodic thyroid screening should be targeted at diabetic patients at risk of thyroid dysfunction i.e. patients with type 1 diabetes, positive thyroid autoantibodies, or TSH concentrations in the upper range of normal. Recognition and prompt correction of thyroid dysfunction will optimise metabolic control and reduce cardiovascular disease risk in patients with diabetes.

**Review criteria**

We searched Medline for relevant articles using various combinations of the search terms: thyroid dysfunction, diabetes mellitus, prevalence, incidence, progression, glucose metabolism, pathogenesis, genetics, cardiovascular disease and screening. In addition we consulted the websites of the major Endocrine and Diabetes professional organisations for current practice guidelines on thyroid disease screening in patients with diabetes.

only

## 1.0 Introduction

Thyroid disorders and diabetes mellitus are the two most common endocrinopathies encountered in practice. Both conditions frequently co-exist and the prevalence of thyroid dysfunction in patients with diabetes is higher than in the general population [1, 2]. Type 1 diabetes (T1DM) and autoimmune thyroid disease (AITD) share common susceptibility genes and frequently occur with other disease models of organ-specific autoimmunity [3]. Unrecognised thyroid dysfunction may impair metabolic control in patients with diabetes [4, 5] and in addition may amplify existing cardiovascular disease risk. The multifaceted relationship between thyroid disease and diabetes mellitus has implications for the clinician. Although recognition and treatment of thyroid dysfunction in diabetic patients will benefit glycaemic control, attenuate cardiovascular risk, and improve general wellbeing, there is no consensus regarding optimal thyroid screening strategies in routine diabetes care. In this review we examine the association between thyroid dysfunction and diabetes mellitus, highlight clinical implications of their inter-dependent relationship, and outline strategies for thyroid disease screening and surveillance in patients with diabetes.

## 2.0 Review Methods

We searched Medline for relevant articles published in the English language from 1970 through October 2009. We used the search terms thyroid dysfunction and diabetes mellitus in conjunction with other terms, including prevalence, incidence, progression, glucose metabolism, pathogenesis, genetics, cardiovascular disease and screening. Further queries were performed with the phrases, subclinical hypothyroidism and subclinical hyperthyroidism and additional relevant publications were sourced from references in individual papers. In addition we consulted the

1  
2  
3 websites of the major Endocrine and Diabetes professional organisations for current  
4  
5 practice guidelines on thyroid disease screening in patients with diabetes.  
6  
7  
8  
9

### 10 **3.0 Frequency of thyroid dysfunction in patients with diabetes**

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Thyroid dysfunction is common in the general population. In a survey in an iodine-replete community in the north east of England (the Whickham survey), the prevalence of thyroid dysfunction was 6.6% in the adult general population [6]. Other large scale studies of thyroid dysfunction in the United States have reported comparable rates in unselected populations [7, 8]. The frequency of thyroid dysfunction rises with age and is higher in females than in males. Studies in various settings have shown that thyroid dysfunction is more common in patients with diabetes than in the background population (table 1) [1, 2, 9-14]. Perros and colleagues observed a prevalence of thyroid dysfunction of 13.4% in 1301 adult diabetes clinic patients with T1DM and type 2 diabetes (T2DM) [1]. A study in a general practice with 223 registered diabetic patients reported a prevalence of thyroid dysfunction of 10.8% [11]. Thyroid dysfunction is more common in patients with T1DM than those with T2DM, and indeed up to a third of patients with T1DM ultimately develop thyroid dysfunction [15]. Postpartum thyroid dysfunction occurs in as much as 25% of women with T1DM [16]. Nevertheless, the frequency of thyroid dysfunction in T2DM still exceeds that of the general population and in some reports equals that of T1DM due to the older age group of patients with T2DM [13, 14].

### 55 **4.0 Autoimmune thyroid disease and type 1 diabetes**

56  
57  
58  
59  
60  
The clinical spectrum of AITD includes Graves' disease (GD), Hashimoto's thyroiditis (HT), and postpartum thyroiditis (PPT). These conditions account for

1  
2  
3 considerable morbidity in affected individuals and are responsible for most thyroid  
4 dysfunction in iodine-replete populations [17]. AITD and T1DM often co-exist in the  
5  
6 same individual and also occur in combination with other organ-specific autoimmune  
7  
8 disorders such as coeliac disease, Addison's disease and autoimmune gastritis [3].  
9  
10 Like T1DM, AITD is a model of organ specific autoimmunity arising from the  
11  
12 interplay of genetic and environmental factors [17]. The immune response in AITD is  
13  
14 characterised by T-cell infiltration of the thyroid gland and the production of  
15  
16 autoreactive antibodies, namely antibodies to thyroid peroxidase (TPOAb) and  
17  
18 thyroglobulin (TgAb) [17]. These antibodies are prevalent in patients with T1DM [2,  
19  
20 12] as well as in their first degree relatives [18], and their presence may predict  
21  
22 subsequent thyroid dysfunction [19].  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 T1DM and AITD also form part of the polyglandular autoimmune syndromes [20].  
33  
34 The rare type 1 polyglandular autoimmune syndrome (PAS-1) results from mutations  
35  
36 in the autoimmune regulator gene (AIRE) and is inherited as an autosomal recessive  
37  
38 trait. PAS-1 typically manifests in childhood or early adolescence and is characterised  
39  
40 by chronic mucocutaneous candidiasis and multiple autoimmune endocrinopathies  
41  
42 including T1DM and AITD. The polyglandular autoimmune syndrome type 2 (PAS-  
43  
44 2) occurs more commonly, is inherited as a polygenic trait, and typically presents in  
45  
46 adulthood with multiple endocrine dysfunction. In many instances T1DM is the  
47  
48 earliest manifestations of these syndromes and the association of T1DM with AITD  
49  
50 occurs more frequently than other disease combinations [20].  
51  
52  
53  
54  
55  
56  
57

58 Several common genetic loci have been implicated in the predisposition to both AITD  
59  
60 and T1DM. Foremost amongst these are genes on the human leukocytic antigen



1  
2  
3 (HLA) locus on the major histocompatibility complex (MHC). A high risk of T1DM  
4 is associated with the HLA-DR3 and HLA-DR4 alleles [21, 22]. Similar associations  
5  
6  
7  
8 with HLA-DR3 have been reported in patients with GD and less consistently in HT  
9  
10 and PPT patients [21, 22]. Other immune regulatory genes outside the HLA loci  
11  
12 contribute to disease risk in AITD and T1DM and include the protein tyrosine  
13  
14 phosphatase-22 (PTPN22) gene and the cytotoxic T lymphocyte-associated antigen-4  
15  
16 (CTLA-4) gene [21, 22]. Moreso, the contribution of these genetic loci to disease  
17  
18 susceptibility appears to be stronger for individuals with co-existent AITD and T1DM  
19  
20 than for patients with single organ disease [21].  
21  
22  
23  
24  
25  
26

## 27 **5.0 Hyperthyroidism and Diabetes**

28  
29 The occurrence of hyperthyroidism in patients with diabetes is greater than in the  
30  
31 general population. Perros et al reported an incidence of 1.0% in diabetic patients [1]  
32  
33 compared to an estimated incidence of approximately 0.3% of the general population  
34  
35 in the Whickham survey [6]. Graves' disease and toxic nodular disease are the most  
36  
37 common causes of hyperthyroidism in the general population while less common  
38  
39 causes include thyroiditis and drug-induced hyperthyroidism.  
40  
41  
42  
43  
44  
45

### 46 *5.1 Metabolic control*

47  
48 Thyroid hormones may influence glucose control through a variety of actions on  
49  
50 intermediary metabolism. Some of these effects become clinically relevant in patients  
51  
52 with co-existent diabetes and hyperthyroidism. Excess thyroid hormones promote  
53  
54 hyperglycaemia by facilitating glucose intestinal absorption, increasing insulin  
55  
56 clearance, and enhancing glycogenolysis and gluconeogenesis [23]. Also,  
57  
58 hyperthyroidism is associated with increased hepatic glucose output, reduced insulin  
59  
60

1  
2  
3 action and increased lipolysis [23]. Accordingly, diabetic patients with overt  
4  
5 hyperthyroidism may experience poor glycaemic control and indeed hyperthyroidism  
6  
7 has been known to precipitate diabetic ketoacidosis in patients with diabetes [24].  
8  
9 Furthermore, the hypermetabolic features of hyperthyroidism may cause diagnostic  
10  
11 confusion with the typical osmotic state of hyperglycaemia. Consequently, severe  
12  
13 diabetes may be missed in patients with thyrotoxicosis, and likewise, life threatening  
14  
15 thyroid storm can be masked by hyperglycaemia [25]. An additional consideration is  
16  
17 the association of low thyroid hormone levels with acute hyperglycaemic states which  
18  
19 may hamper the accurate interpretation of thyroid function tests in patients with  
20  
21 uncontrolled diabetes [10, 26].  
22  
23  
24  
25  
26  
27  
28

## 29 5.2 *Cardiovascular disease risk*

30  
31 In addition to its impact on glycaemic control hyperthyroidism may add to  
32  
33 cardiovascular disease risk in patients with diabetes [reviewed in 27]. Prominent  
34  
35 cardiovascular features such as tachycardia, arrhythmias, congestive cardiac failure,  
36  
37 and systolic hypertension are well recognised manifestations of thyrotoxicosis.  
38  
39 Furthermore, an increased cardiovascular mortality has been reported in patients with  
40  
41 overt [28] as well as subclinical hyperthyroidism, defined as suppressed TSH in the  
42  
43 presence of normal thyroid hormone levels [29, 30]. Atrial fibrillation is reported in as  
44  
45 much as 10-15% of patients with overt hyperthyroidism and individuals with  
46  
47 subclinical hyperthyroidism are more likely to develop atrial fibrillation than  
48  
49 euthyroid persons [31]. Cardiovascular mortality in hyperthyroidism is linked to older  
50  
51 age, cardiac arrhythmias, or pre-existing organic heart disease [27].  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 6.0 **Hypothyroidism and Diabetes**

1  
2  
3 Hypothyroidism is the most common form of thyroid dysfunction encountered in  
4  
5 patients with diabetes. The prevalence of hypothyroidism was 5.7% in diabetic  
6  
7 patients [1] compared to a prevalence of 1.1% in the Whickham survey [6]. Chronic  
8  
9 autoimmune thyroiditis accounts for most cases of hypothyroidism in iodine sufficient  
10  
11 countries. Other causes include hypothyroidism secondary to radioiodine therapy,  
12  
13 surgery, or pituitary disease.  
14  
15  
16  
17  
18  
19

### 20 6.1 *Metabolic control*

21  
22 In patients with diabetes, hypothyroidism may influence metabolic control through  
23  
24 effects on glucose metabolism which are opposite to those seen in hyperthyroidism.  
25  
26 These effects include reductions in hepatic glucose output, gluconeogenesis, and  
27  
28 peripheral glucose utilization. The net effect of these processes is a predisposition to  
29  
30 hypoglycaemia [32]. Frequent hypoglycaemic episodes were documented in children  
31  
32 and adolescents with diabetes and subclinical hypothyroidism i.e. elevated TSH and  
33  
34 normal thyroid hormones [4]. Moreso, correction of hypothyroidism led to  
35  
36 improvement in hypoglycaemic symptoms in these patients [4]. Glycaemic status may  
37  
38 in turn influence thyroid function. A low T3 state is observed in patients with severe  
39  
40 hyperglycaemia [26]. Celani and colleagues reported a high frequency of thyroid  
41  
42 function abnormalities in acute hospital admissions with poorly controlled diabetes  
43  
44 [10]. These abnormalities were mostly subclinical and reverted to normal with  
45  
46 improvement in blood glucose control in the majority of patients [10]. Co-existent  
47  
48 diabetes may affect the efficacy of thyroid hormone treatment in patients with  
49  
50 hypothyroidism. A recent study in elderly patients on L-thyroxine treatment showed  
51  
52 that the presence of diabetes was independently associated with inadequate thyroid  
53  
54 hormone replacement, an association which was not seen with other chronic disorders.  
55  
56  
57  
58  
59  
60

1  
2  
3 [33]. A further interaction may result from the use of the anti-diabetic agent,  
4 metformin, which has been shown to suppress TSH concentrations in diabetic patients  
5  
6 on thyroxine treatment [34].  
7  
8  
9

## 10 11 12 13 6.2 *Cardiovascular disease risk*

14  
15 Diabetes is associated with significant cardiovascular risk [35]. Hypothyroidism may  
16  
17 add to this risk through independent associations with atherosclerotic heart disease  
18  
19 [reviewed in 36]. In early case control studies, postmortem atherosclerosis was found  
20  
21 to be more common in patients with hypothyroidism than in euthyroid control  
22  
23 subjects [37]. In the 20-year follow up of the Wickham study, no relationship was  
24  
25 demonstrable between baseline thyroid dysfunction and subsequent coronary heart  
26  
27 disease although this cohort included patients who received treatment with  
28  
29 levothyroxine [38]. In contrast a population-based cross sectional study of 1149 older  
30  
31 female participants, the Rotterdam study, showed an association between subclinical  
32  
33 hypothyroidism and myocardial infarction [39]. In addition hypothyroidism may  
34  
35 magnify cardiovascular disease risk through multiple interactions with cardiovascular  
36  
37 disease indices such as dyslipidaemia and hypertension, features which overlap with  
38  
39 the typical phenotype of insulin resistance.  
40  
41  
42  
43  
44  
45  
46  
47

48  
49 Dyslipidaemia is a well-recognised association of hypothyroidism and typically  
50  
51 consists of raised levels of total cholesterol, apolipoprotein B, low density lipoprotein  
52  
53 (LDL) cholesterol, and reduced levels of high density lipoprotein (HDL) cholesterol  
54  
55 [40]. Such lipid abnormalities are partly reversible with thyroxine treatment in  
56  
57 patients with co-existent diabetes [41]. Several studies have reported inter-dependent  
58  
59 associations between thyroid status, dyslipidaemia, and insulin resistance. In  
60

1  
2  
3 euthyroid persons low normal thyroid hormone levels were associated with  
4 hyperlipidaemia and insulin resistance [42]. Furthermore, Bakker and colleagues  
5 demonstrated a positive correlation between thyrotropin (TSH) and LDL cholesterol  
6 in euthyroid individuals, an association which was apparent in insulin resistant  
7 subjects but was absent in insulin sensitive subjects [43]. Similar interactions have  
8 been demonstrated in diabetic patients [44] and taken together these studies suggest a  
9 modifying influence of insulin sensitivity on the effects of hypothyroidism on lipid  
10 metabolism.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22  
23  
24 A relationship between hypothyroidism and obesity has mostly been inferred from  
25 studies in historical cohorts [45-46]. More contemporary data suggest an association  
26 between body mass index and low-normal thyroid hormones or high-normal TSH  
27 concentrations [47]. However, these findings were not confirmed by others [48]. The  
28 effects of thyroid hormones on blood pressure are also well documented. Diastolic  
29 hypertension is seen in hypothyroidism due to increases in systemic vascular  
30 resistance [36]. Also, increased central arterial stiffness which is reversible with  
31 thyroxine therapy has been described in overtly hypothyroid patients [49].  
32 Furthermore, hypothyroidism is associated with endothelial dysfunction as determined  
33 by increased arterial intima media thickness or impairment in flow-mediated  
34 endothelial dependent vasodilatation [50]. A study in healthy euthyroid men showed  
35 positive correlations between TSH, endothelial dysfunction and insulin resistance [51]  
36 lending further support to the three-way relationship between thyroid status, insulin  
37 resistance and cardiovascular disease risk.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 7.0 Subclinical hypothyroidism and diabetes

1  
2  
3 Subclinical hypothyroidism is defined as an elevated TSH concentration in the  
4 presence of normal thyroid hormones [52]. This biochemical diagnosis accounts for a  
5  
6 substantial proportion of thyroid dysfunction encountered in patients with diabetes. A  
7  
8 prevalence rate of 5.0% was reported by Perros and colleagues in the hospital  
9  
10 outpatient diabetes setting [1] while Chubb *et al* reported a prevalence of 8.6% in  
11  
12 community-based female diabetic-patients [14]. A study in an adolescent population  
13  
14 of patients with diabetes detected a prevalence of 6% [4]. With the advent of sensitive  
15  
16 assays for TSH measurements subclinical hypothyroidism will increasingly be  
17  
18 diagnosed in healthy individuals with no overt features of thyroid disease. Despite a  
19  
20 considerable amount of research the significance of these subclinical states remain  
21  
22 unsettled. The implications of subclinical hypothyroidism in the patient with diabetes  
23  
24 will depend on its likelihood of progression to overt disease, its impact on diabetes  
25  
26 metabolic control, as well as the potential for therapeutic benefits with LT-4.  
27  
28  
29  
30  
31  
32  
33  
34  
35

### 36 7.1 *Metabolic control*

37  
38 Only few studies have specifically addressed the influence of subclinical  
39  
40 hypothyroidism on glycaemic control. One study in children with diabetes showed  
41  
42 that the onset of AITD defined a sub-group of diabetic patients with more severe  
43  
44 metabolic disease [5]. In a cross-sectional study in patients with T1DM it was  
45  
46 suggested that recurrent hypoglycaemic episodes, inability to lose weight, and mild  
47  
48 dyslipidaemia were pointers to underlying hypothyroidism, both overt and subclinical  
49  
50 [53]. A retrospective case control study by Mohn *et al* compared metabolic control  
51  
52 and frequency of hypoglycaemia before and after diagnosis of hypothyroidism in  
53  
54 children and adolescents with T1DM [4]. Subclinical hypothyroidism was associated  
55  
56  
57  
58  
59  
60

1  
2  
3 with an increased frequency of hypoglycaemic episodes which were abolished with  
4  
5 LT-4 treatment [4].  
6  
7  
8  
9

### 10 7.2 *Progression to overt hypothyroidism*

11  
12 In the Whickham study the rate of progression from subclinical hypothyroidism to  
13  
14 overt hypothyroidism was 2.6% per year in antibody-negative patients and 4.3% in  
15  
16 antibody-positive patients with higher TSH concentrations [54]. It does not appear  
17  
18 that the rate of progression to overt hypothyroidism is much higher for patients with  
19  
20 diabetes. Gray and colleagues recorded a progression rate of 5% per annum in  
21  
22 diabetic patients with positive thyroid microsomal antibodies [55]. However, in the  
23  
24 community-based Fremantle study none of the female patients with T2DM and  
25  
26 subclinical hypothyroidism progressed to overt hypothyroidism over a 5-year period  
27  
28 thus questioning the significance of subclinical hypothyroidism in patients with type 2  
29  
30 diabetes [14].  
31  
32  
33  
34  
35  
36  
37  
38

### 39 7.3 *Cardiovascular disease risk*

40  
41 While there is compelling evidence to support an association between overt  
42  
43 hypothyroidism and atherosclerotic heart disease, this relationship remains less certain  
44  
45 for subclinical hypothyroidism. In the Rotterdam study subclinical hypothyroidism  
46  
47 was associated with myocardial infarction [39] an association which was unproven in  
48  
49 the follow-up of the Whickham study [38]. Several cardiovascular abnormalities have  
50  
51 been documented in patients with subclinical hypothyroidism including diastolic  
52  
53 dysfunction, hypertension, increased arterial stiffness, and endothelial dysfunction  
54  
55 [36, 52]. Studies on lipid profiles have given highly variable results ranging from  
56  
57 increased [7] to even lower cholesterol levels [39] in patients with subclinical  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

hypothyroidism compared to euthyroid controls. Furthermore, evidence from various small-sized randomised control trials has given conflicting results on the benefits of LT-4 treatment on lipid parameters in subclinical hypothyroidism [56]. A meta-analysis of 13 studies comprising 247 patients concluded that LT-4 treatment was associated with improvements in some lipid parameters including total cholesterol, LDL cholesterol and apoB levels [56].

To summarise, the existing evidence is inconclusive regarding the benefits of LT-4 treatment on cardiovascular indicators in patients with subclinical hypothyroidism. However, the evidence from a small number of case series in children with diabetes suggest that co-existent hypothyroidism, both overt and subclinical, may define a subset of patients with more severe disease [4, 5, 53] and that LT-4 treatment may be beneficial in reducing the frequency of hypoglycaemic episodes in these patients [4]. Moreover, progression to overt disease is to be expected in a proportion of patients which will add to cardiovascular disease risk. Thus, it seems reasonable, in our opinion to consider treatment of subclinical hypothyroidism in patients with diabetes. Adequately powered randomised controlled trials are however required to determine the impact of such therapy on metabolic and cardiovascular parameters.

## **8.0 Screening strategies for thyroid dysfunction in diabetic patients**

There is little consensus on thyroid disease screening strategies in routine diabetes care. The main discrepancies relate to the choice of thyroid function tests, the intervals between testing, whether routine screening is indicated in all diabetic patients, and whether a specific screening policy is at all necessary in diabetic patients. These uncertainties are reflected in the guidelines published by the major



1  
2  
3 endocrine and diabetes societies on thyroid disease screening (table 2) [57-64]. The  
4  
5 recommendations from some guidelines are vague and sometimes contradictory. For  
6  
7 example, not all guidelines explicitly mention thyroid testing in patients with diabetes  
8  
9 [59, 62], clearly distinguish type 1 from type 2 diabetes [57], or include specific  
10  
11 reference to thyroid disease screening in patients with T2DM [58, 59, 64]. In the  
12  
13 absence of definitive guidance local policies and practices are likely to remain  
14  
15 discrepant as previously observed [65].  
16  
17  
18  
19  
20  
21

### 22 8.1 Choice of tests

23  
24 Many laboratories routinely measure FT4 and TSH as first line tests for thyroid  
25  
26 function although measurement of TSH-alone is adequate for screening purposes in a  
27  
28 stable outpatient setting [66]. Most guidelines advocate measuring TSH and thyroid  
29  
30 antibodies at diagnosis of diabetes, and then testing only TSH at subsequent visits [61,  
31  
32 63-64]. TSH is the most sensitive means of detecting thyroid dysfunction and  
33  
34 sensitive third-generation assays are readily available in most modern laboratories. A  
35  
36 normal TSH concentration has a high negative predictive value for excluding thyroid  
37  
38 disease, and changes in TSH concentrations usually precede changes in free thyroid  
39  
40 hormone levels in the development of thyroid failure [66]. However, measurement of  
41  
42 TSH alone may be inappropriate in specific clinical situations such as in cases of  
43  
44 suspected pituitary disease or in monitoring patients with known thyroid disease. TSH  
45  
46 alone will also be inadequate where thyroid disease is suspected in patients with acute  
47  
48 presentations such as diabetic ketoacidosis, hyperosmolar states and recurrent  
49  
50 hypoglycaemic episodes. Estimation of FT4 as well as TSH will be necessary in these  
51  
52 instances and these may need to be repeated after the acute illness has subsided to  
53  
54 distinguish true thyroid dysfunction from non-thyroidal illness.  
55  
56  
57  
58  
59  
60

## 8.2 Screening in type 1 diabetes

Thyroid autoimmunity is especially common in T1DM and up to a third of patients with T1DM eventually develop thyroid dysfunction [15]. In these patients thyroid dysfunction may be asymptomatic or its clinical features may be masked by features of poor diabetes metabolic control. Thus, a systematic approach to thyroid disease screening seems justified in T1DM. Routine screening will identify a significant proportion of patients with thyroid disease and is unlikely to incur excessive costs given that patients with T1DM represent a lesser fraction of all diabetic patients. Existing guidelines recommend screening all patients with T1DM at baseline i.e. at the point of diagnosis or initial contact (table 2). However, there are differences with respect to subsequent surveillance strategies. While some practice guidelines do not specify the exact interval of periodic testing [57, 58] others recommend annual [61] or two-yearly testing [63, 64], with more frequent tests suggested for antibody-positive patients [64] or patients with goitre [58, 64] or other autoimmune diseases [58] (table 2).

## 8.3 Screening in type 2 diabetes

The case for annual screening in patients with T2DM is less clear-cut. A number of guidelines are either not specific regarding routine monitoring [58, 64] or explicitly recommend against routine annual screening in patients with T2DM [61] (table 2). In one report the 5-year incidence of thyroid dysfunction in older patients with T2DM was not significantly higher when compared to subjects without diabetes [67]. The findings by Chubb *et al* of 0% progression rate to overt hypothyroidism in women with T2DM and subclinical hypothyroidism casts further doubts on the value of

1  
2  
3 routine annual screening in T2DM [14]. Moreso, it is debatable whether a routine  
4 annual screening strategy in patients with T2DM who constitute the bulk of diabetic  
5 patients will be cost effective [65]. Although relatively inexpensive at the unit level,  
6 the total annual cost of thyroid function testing in the United Kingdom was estimated  
7 at over £30 million [68]. Some of this expenditure will be attributable to routine  
8 periodic surveillance in patients with diabetes and other groups at high risk of thyroid  
9 dysfunction. The rising prevalence of T2DM coupled with the increasing availability  
10 of sensitive thyroid hormone assays will see a growing number of diabetic patients  
11 diagnosed with subclinical thyroid dysfunction in years to come. Whether such  
12 individuals with minor degrees of thyroid dysfunction will merit treatment remains  
13 unresolved but such biochemical diagnoses will nonetheless generate additional work-  
14 loads, laboratory costs, and patient anxiety.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 In patients with T2DM it may suffice to undertake selective periodic screening using  
35 established laboratory predictors of thyroid dysfunction as risk stratification tools.  
36 Thyroid antibodies and serum TSH have proven useful in identifying diabetic patients  
37 at the greatest risk of thyroid dysfunction. Studies have shown that serum TSH  
38 concentrations in the upper range of normal predict the development of  
39 hypothyroidism. In the Whickham survey, a TSH concentration above 2.0 mU/L was  
40 associated with an increased risk of future hypothyroidism in the general population  
41 [54]. In a longitudinal study in hospital clinic patients with T1DM and T2DM, a TSH  
42 concentration > 1.53 mU/L predicted subsequent hypothyroidism [69]. Furthermore,  
43 the authors of this study showed that restricting thyroid testing to only patients with a  
44 TSH > 1.53 mU/L was cost effective [69]. [A recent study in a general population  
45 \(n=1184\) demonstrated that a TSH concentration > 2.5 mU/L predicted the long-term](#)  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 | risk of hypothyroidism [70]. TPOAbs also predict thyroid dysfunction in patients with  
4  
5  
6 | diabetes [15, 19]. Umpierrez *et al* prospectively followed-up patients with T1DM over  
7  
8  
9 | a period of 18 years and showed that TPOAb-positive patients were 18 times more  
10  
11 | likely to develop hypothyroidism than antibody-negative patients [15].  
12  
13

#### 14 8.4 Recommended screening algorithm

15  
16  
17 | With the above considerations in mind therefore a pragmatic approach would be to  
18  
19 | measure TPOAb and TSH in all diabetic patients at baseline, and then restrict  
20  
21 | subsequent annual testing to only those patients with T1DM, positive antibodies, or  
22  
23 | TSH concentration in the upper range of normal. Measurement of FT4 may be  
24  
25 | included in the baseline assessment in some cases to provide a preliminary picture of  
26  
27 | the thyroid-pituitary relationship. If this is normal then a strategy of TSH alone, with  
28  
29 | cascade to FT4 if necessary will suffice for subsequent annual testing. A simplified  
30  
31 | algorithm is suggested in figure 1. Although this approach will fail to identify type 2  
32  
33 | diabetic patients with hyperthyroidism the frequency of hyperthyroidism in T2DM is  
34  
35 | not as significant as to warrant a separate screening approach. This algorithm will  
36  
37 | nonetheless ensure that those diabetic patients at greatest risk of thyroid dysfunction  
38  
39 | such as patients with T1DM, antibody-positive status or TSH in the upper reference  
40  
41 | range are monitored routinely. We have suggested a TSH concentration > 2.0 mU/L  
42  
43 | as a threshold for subsequent routine testing based on the findings of the Whickham  
44  
45 | survey which demonstrated a higher risk of hypothyroidism in patients with baseline  
46  
47 | TSH above this concentration [54]. Others have reported similar but slightly differing  
48  
49 | TSH cut-offs and further studies will be required to clarify the optimal TSH  
50  
51 | thresholds for predicting thyroid dysfunction [69, 70].  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 9.0 Conclusion

Patients with diabetes are at an increased risk of thyroid dysfunction. Recent decades have seen a growing understanding of the pleiotropic effects of thyroid hormones on various vascular and metabolic processes. Furthermore, insights are being developed into the complex interactions, at the phenotypic and molecular levels, between thyroid dysfunction, insulin resistance, and cardiovascular risk. Thus, our understanding has shifted from the simplistic concept of thyroid dysfunction as a benign disorder of hormone secretion to a more complete appreciation of its multiple deleterious effects on cardiovascular and metabolic function. Unrecognised thyroid dysfunction will amplify cardiovascular risk in diabetic patients although the significance of mild degrees of thyroid dysfunction is yet to be clarified. The increased frequency of thyroid dysfunction in diabetes calls for a systematic approach to thyroid testing. Yet screening practices vary widely and pragmatic guidelines are lacking. At present, a selective annual screening strategy may allow monitoring to be streamlined to those diabetic patients at the greatest risk of thyroid dysfunction such as those with T1DM, baseline positive antibodies or TSH concentrations in the upper half of the normal reference range.



1  
2  
3 **Table 1:** Studies of prevalence of thyroid dysfunction in patients with diabetes

4  
5 **Table 2:** Recommendations from major endocrine and diabetes practice guidelines on  
6 thyroid screening in patients with diabetes  
7  
8

9  
10 **Figure 1:** Suggested simplified screening and monitoring algorithm for thyroid  
11 dysfunction patients with diabetes  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review Only

1  
2  
3 **Legend**  
4

5  
6 **Table 1:**  
7

8 \*median  
9

10 \*\* SD  
11

12 + These were patients with poor glycaemic control; thyroid dysfunction mostly  
13 improved with correction of hyperglycaemia.  
14

15 NA = not applicable  
16

17  
18  
19 **Figure 1:**  
20

21 \* FT4 should be measured if TSH is abnormal.  
22  
23

24  
25 Table 2:  
26

27 \*Only associations with available guidelines on thyroid disease screening or diabetes  
28 management were included. Guidelines were unavailable for the following  
29 associations: Asia Oceania Thyroid Association, European Thyroid Association,  
30 Australia diabetes Association, and European Association for the study of Diabetes.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Author contribution**

All authors contributed to the drafting and critical revision of the manuscript and approved the final draft of the article.

**Funding:** None

**Declaration of competing interests:** Nothing to declare

**Acknowledgements:** None

Or Peer Review Only



## References

1. Perros P, McCrimmon RJ, Shaw G, Frier BM. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. *Diabet Med.* 1995; **12**:622-627.
2. Kordonouri O, Klinghammer A, Lang EB, Grüters-Kieslich A, Grabert M, Holl RW. Thyroid autoimmunity in children and adolescents with type 1 diabetes: a multicenter survey. *Diabetes Care.* 2002; **25**:1346-1350
3. Barker JM. Clinical review: Type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening Clinical review: Type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. *J Clin Endocrinol Metab.* 2006; **91**:1210-1217.
4. Mohn A, Di Michele S, Di Luzio R, Tumini S, Chiarelli F. The effect of subclinical hypothyroidism on metabolic control in children and adolescents with Type 1 diabetes mellitus. *Diabet Med.* 2002; **19**:70-73.
5. Franzese A, Buono P, Mascolo M, Leo AL, Valerio G. Thyroid autoimmunity starting during the course of type 1 diabetes denotes a subgroup of children with more severe diabetes. *Diabetes Care.* 2000; **23**:1201-1202.
6. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Wickham survey. *Clin Endocrinol (Oxf).* 1977; **7**:481-493.
7. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. *Arch Intern Med.* 2000; **160**:526-534.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
8. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab.* 2002; **87**: 489-499.
9. Gray RS, Borseley DQ, Seth J, Herd R, Brown NS, Clarke BF. Prevalence of subclinical thyroid failure in insulin-dependent diabetes. *J Clin Endocrinol Metab.* 1980; **50**: 1034-1037.
10. Celani MF, Bonati ME, Stucci N. Prevalence of abnormal thyrotropin concentrations measured by a sensitive assay in patients with type 2 diabetes mellitus. *Diabetes Res.* 1994; **27**:15-25.
11. Smithson MJ. Screening for thyroid dysfunction in a community population of diabetic patients. *Diabet Med.* 1998; **15**: 148-150.
12. Hansen D, Bennedbaek FN, Hansen LK, Hoier-Madsen M, Jacobsen BB, Hegedüs L. Thyroid function, morphology and autoimmunity in young patients with insulin-dependent diabetes mellitus. *Eur J Endocrinol.* 1999; **140**: 512-518.
13. Radaideh AR, Nusier MK, Amari FL, Bateiha AE, El-Khateeb MS, Naser AS, Ajlouni KM. Thyroid dysfunction in patients with type 2 diabetes mellitus in Jordan. *Saudi Med J.* 2004; **25**:1046-1050.
14. Chubb SA, Davis WA, Inman Z, Davis TM. Prevalence and progression of subclinical hypothyroidism in women with type 2 diabetes: the Fremantle Diabetes Study. *Clin Endocrinol (Oxf).* 2005; **62**: 480-486.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
15. Umpierrez GE, Latif KA, Murphy MB, Lambeth HC, Stentz F, Bush A, et al. Thyroid dysfunction in patients with type 1 diabetes: a longitudinal study. *Diabetes Care*. 2003; **26**: 1181-1185.
  16. Gerstein HC. Incidence of postpartum thyroid dysfunction in patients with type I diabetes mellitus. *Ann Intern Med*. 1993; **118**: 419-423.
  17. Weetman AP and McGregor AM. Autoimmune thyroid disease: further developments in our understanding. *Endocr Rev*. 1994; **15**: 788-830.
  18. Hanukoglu A, Mizrahi A, Dalal I, Admoni O, Rakover Y, Bistrizter Z, et al. Extrapancreatic autoimmune manifestations in type 1 diabetes patients and their first-degree relatives: a multicenter study. *Diabetes Care*. 2003; **26**:1235-1240.
  19. González GC, Capel I, Rodríguez-Espinosa J, Mauricio D, de Leiva A, Pérez A. Thyroid autoimmunity at onset of type 1 diabetes as a predictor of thyroid dysfunction. *Diabetes Care*. 2007; **30**:1611-1612.
  20. [Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. \*J Clin Endocrinol Metab\*. 2003; \*\*88\*\*: 2983-92.](#)
  21. Levin L, Tomer Y. The etiology of autoimmune diabetes and thyroiditis: evidence for common genetic susceptibility. *Autoimmun Rev*. 2003; **2**: 377-386.
  22. Pearce SH, Merriman TR. Genetics of type 1 diabetes and autoimmune thyroid disease. *Endocrinol Metab Clin North Am*. 2009; **38**: 289-301, vii-viii.
  23. Potenza M, Via MA, Yanagisawa RT. Excess thyroid hormone and carbohydrate metabolism. *Endocr Pract*. 2009; **15**: 254-262.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
24. Bhattacharyya A, Wiles PG. Diabetic ketoacidosis precipitated by thyrotoxicosis. *Postgrad Med J.* 1999; **75**:291-292.
  25. Kunishige M, Sekimoto E, Komatsu M, Bando Y, Uehara H, Izumi K. Thyrotoxicosis masked by diabetic ketoacidosis: a fatal complication. *Diabetes Care.* 2001; 24: 171.
  26. Naeije R, Golstein J, Clumeck N, Meinhold H, Wenzel KW, Vanhaelst L. A low T3 syndrome in diabetic ketoacidosis. *Clin Endocrinol (Oxf).* 1978; 8: 467-472 Naeije R, Golstein J, Clumeck N, Meinhold H, Wenzel KW, Vanhaelst L. A low T3 syndrome in diabetic ketoacidosis. *Clin Endocrinol (Oxf).* 1978; **8**: 467-472
  27. Boelaert K, Franklyn JA. Thyroid hormone in health and disease. *J Endocrinol.* 2005; **187**: 1-15.
  28. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. *N Engl J Med.* 1998 **12**; 338: 712-8.
  29. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. *Lancet.* 2001; **358**: 861-865.
  30. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. *Eur J Endocrinol.* 2005; **152**: 1-9.
  31. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. *N Engl J Med.* 1994; **331**: 1249-1252.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
32. Mouradian M, Abourizk N. Diabetes mellitus and thyroid disease. *Diabetes Care*. 1983; **6**: 512-520.
33. Somwaru LL, Arnold AM, Joshi N, Fried LP, Cappola AR. High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. *J Clin Endocrinol Metab*. 2009; **94**: 1342-1345.
34. Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. *J Clin Endocrinol Metab*. 2006; **91**: 225-227.
35. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med*. 1998; **339**:229-234.
36. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. *J Clin Endocrinol Metab*. 2003; **88**: 2438-2444.
37. Steinberg AD. Myxedema and coronary artery disease--a comparative autopsy study. *Ann Intern Med*. 1968; **68**: 338-344.
38. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. *Thyroid*. 1996; **6**: 155-160.
39. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. *Ann Intern Med*. 2000 **15**; 13: 270-278.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
40. Pearce EN. Hypothyroidism and dyslipidemia: modern concepts and approaches. *Curr Cardiol Rep.* 2004; 6:451-456.
41. Gray RS, Smith AF, Clarke BF. Hypercholesterolemia in diabetics with clinically unrecognised primary thyroid failure. *Horm Metab Res.* 1981; **13**: 508-510.
42. Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. *J Clin Endocrinol Metab.* 2007; **92**: 491-496.
43. Bakker SJ, ter Maaten JC, Popp-Snijders C, Slaets JP, Heine RJ, Gans RO. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. *J Clin Endocrinol Metab.* 2001; **86**: 1206-1211.
44. Chubb SA, Davis WA, Davis TM. Interactions among thyroid function, insulin sensitivity, and serum lipid concentrations: the Fremantle diabetes study. *J Clin Endocrinol Metab.* 2005; **90**: 5317-5320.
45. Rimm AA, Werner LH, Yserloo BV, Bernstein RA. Relationship of obesity and disease in 73,532 weight-conscious women. *Public Health Rep.* 1975; **90**: 44-51.
46. Baron DN. Hypothyroidism; its aetiology and relation to hypometabolism, hypercholesterolaemia, and increase in body-weight. *Lancet.* 1956; **271**: 277-281.
47. Knudsen N, Laurberg P, Rasmussen LB, Bülow I, Perrild H, Ovesen L, Jørgensen T. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. *J Clin Endocrinol Metab.* 2005; **90**: 4019-4024.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
48. Manji N, Boelaert K, Sheppard MC, Holder RL, Gough SC, Franklyn JA. Lack of association between serum TSH or free T4 and body mass index in euthyroid subjects. *Clin Endocrinol (Oxf)*. 2006; **64**: 125-128.
49. Obuobie K, Smith J, Evans LM, John R, Davies JS, Lazarus JH. Increased central arterial stiffness in hypothyroidism. *J Clin Endocrinol Metab*. 2002; **87**: 4662-4666.
50. Owen PJ, Sabit R, Lazarus JH. Thyroid disease and vascular function. *Thyroid*. 2007; **17**: 519-524.
51. Fernández-Real JM, López-Bermejo A, Castro A, Casamitjana R, Ricart W. Thyroid function is intrinsically linked to insulin sensitivity and endothelium-dependent vasodilation in healthy euthyroid subjects. *J Clin Endocrinol Metab*. 2006; **91**: 3337-3343.
52. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. *Endocr Rev*. 2008; **29**: 76-131.
53. Leong KS, Wallymahmed M, Wilding J, MacFarlane I. Clinical presentation of thyroid dysfunction and Addison's disease in young adults with type 1 diabetes. *Postgrad Med J*. 1999; **75**: 467-470.
54. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. *Clin Endocrinol (Oxf)*. 1995; **43**:55-68.
55. Gray RS, Borseley DQ, Irvine WJ, Seth J, Clarke BF. Natural history of thyroid function in diabetics with impaired thyroid reserve: a four year controlled study. *Clin Endocrinol (Oxf)*. 1983; **19**: 445-451.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
56. Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. *J Clin Endocrinol Metab.* 2000; **85**: 2993-3001.
57. Ladenson PW, Singer PA, Ain KB, Bagchi N, Bigos ST, Levy EG, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. *Arch Intern Med.* 2000; **160**:1573-1575
58. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, et al; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. *Endocr Pract.* 2002; **8**: 457-469.
59. U.S. Preventive Services Task Force. Screening for thyroid disease: recommendation statement. *Ann Intern Med.* 2004; **140**: 125-127.
60. International diabetes federation. Global guidelines for type 2 diabetes [www.idf.org/webdata/docs/IDF%20GGT2D.pdf](http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf). Accessed October 2009.
61. British Thyroid Association and Association of Clinical Biochemistry Guidelines 2006. [www.british-thyroid-association.org/info-for-patients/Docs/TFT\\_guideline\\_final\\_version\\_July\\_2006.pdf](http://www.british-thyroid-association.org/info-for-patients/Docs/TFT_guideline_final_version_July_2006.pdf). Accessed October 2009.
62. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, et al; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. *Endocr Pract.* 2007; **13 Suppl 1**:1-68.



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
63. Kordonouri O, Maguire AM, Knip M, Schober E, Lorini R, Holl RW, et al. Other complications and associated conditions with diabetes in children and adolescents. *Pediatr Diabetes*. 2009; **10 Suppl 12**:204-210.
64. American Diabetes Association. Standards of medical care in diabetes-- 2009. *Diabetes Care*. 2009; **32 Suppl 1**:S13-61.
65. Badman MK, Chowdhury TA. Should thyroid function tests be done annually in all patients with diabetes? *Diabet Med*. 2002; **19 Suppl 3**:7-9
66. Stockigt JR. Case finding and screening strategies for thyroid dysfunction. *Clinica Chimica Acta*. 2002; **315**:111-124.
67. Gopinath B, Wang JJ, Kifley A, Wall JR, Leeder SR, Mitchell P. Type 2 diabetes does not predict incident thyroid dysfunction in the elderly. *Diabetes Res Clin Pract*. 2008; **82**: e11-3.
68. Beckett GJ, Toft AD. First-line thyroid function tests – TSH alone is not enough. *Clin Endocrinol (Oxf)*. 2003; **58**: 20-21.
69. Warren RE, Perros P, Nyirenda MJ, Frier BM. Serum thyrotropin is a better predictor of future thyroid dysfunction than thyroid autoantibody status in biochemically euthyroid patients with diabetes: implications for screening. *Thyroid*. 2004; **14**: 853-857.
70. [Walsh JP, Bremner AP, Feddema P, Leedman PJ, Brown SJ, O'Leary P. Thyrotropin and Thyroid Antibodies as Predictors of Hypothyroidism: A 13-Year, Longitudinal Study of a Community-Based Cohort Using Current Immunoassay Techniques. J Clin Endocrinol Metab. 2010. \[Published electronically ahead of print; doi:10.1210/jc.2009-1977\]](#)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

**Table 1: Prevalence of thyroid dysfunction in patients with diabetes mellitus**

Study [Reference]	Sample size	Female (%)	Age (yrs)		Study setting	Type of diabetes	Thyroid dysfunction %		
			Mean	Range			Total	Males	Females
Gray et al, 1980 [9]	605	51	Not stated	21-84	Hospital clinic	T1DM	12	6.1	17
Celani et al, 1994 [10]	290	55	61	40-93	Hospitalised patients <sup>+</sup>	T2DM	31.4	19.8	40.9
Perros et al, 1995 [1]	1310	58	54	13-95	Hospital clinic	T1DM, T2DM	13.4	8.8	16.8
Smithson et al, 1998 [11]	223	43	65	17-93	Community practice	T1DM, T2DM	10.8	2.6	9.5
Hansen et al, 1999 [12]	105	51	13*	2-18	Community study	T1DM	4.8	1.8	8
Kordonouri et al, 2002 [2]	7097	51	12	0.3-20	Multi-centre study	T1DM	9.5	9.3	10.1
Radaideh et al, 2004 [13]	908	53	50	26-85	Hospital clinic	T2DM	12.5	6.5	17.5
Chubb et al, 2005 [14]	382	100	64	12.5**	Community study	T2DM	10.4	NA	10.4

\*median

\*\* SD

+ These were patients with poor glycaemic control; thyroid dysfunction mostly improved with correction of hyperglycaemia.

NA = not applicable

**Table 2: Recommendations from major endocrine and diabetes practice guidelines on thyroid screening in patients with diabetes**

Guidelines*	Type 1 diabetes	Type 2 diabetes	Comments
American Thyroid Association guidelines for detection of thyroid dysfunction, 2000 [57]	Patients with diabetes may require more frequent testing	Patients with diabetes may require more frequent testing.	Recommends TSH from 35 yrs, and every 5 yrs thereafter in all adults; high risk persons may require more frequent tests. Diabetes mentioned as high risk but does not distinguish between T1DM or T2DM
American Association of Clinical Endocrinologists, Thyroid disease clinical Practice guidelines, 2002 [58]	Thyroid palpation and TSH at diagnosis and at regular intervals, especially if goitre or other autoimmune disease present.	Thyroid palpation and TSH at diagnosis and at regular intervals, especially if goitre or other autoimmune disease present.	No specific recommendation for T2DM
U.S. Preventive Services Task Force recommendation statement, 2004 [59]	No specific mention	No specific mention	Insufficient evidence to recommend for or against routine screening in adults
International diabetes federation global guidelines for type 2 diabetes, 2005 [60]	Not applicable	Not mentioned	Assessment of thyroid function recommended in pregnant patients with diabetes
British Thyroid Association and Association of Clinical Biochemistry Guidelines, 2006 [61]	TSH and antibodies at baseline, and then TSH every year	TFT at baseline but routine annual TFT not recommended	TSH and antibodies recommended in diabetic patients in pregnancy and postpartum
American Association of Clinical Endocrinologists diabetes guidelines, 2007 [62]	Not specifically mentioned	Not specifically mentioned	Assessment of thyroid function in pregnant patients with diabetes recommended
International society for paediatric and Adolescent Diabetes guidelines, 2009 [63]	TSH and antibody at diagnosis, then 2-yearly; more frequently if goitre, antibodies or symptoms	Not applicable	Guideline focused on paediatric and adolescent diabetes
American Diabetes Association. Standards of medical care in diabetes, 2009 [64]	TSH and antibody at diagnosis, then annual or 2-yearly TSH	Not specifically mentioned	Thyroid palpation in all diabetic patients; TSH in adults > 50 yrs, or patients with dyslipidaemia

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1: Simplified screening and monitoring algorithm for thyroid dysfunction patients with diabetes

\* FT4 should be measured if TSH is abnormal.  
254x190mm (72 x 72 DPI)